2 ANNEX I CLINICAL EXAMINATIONS, SAMPLING PROCEDURES, DIAGNOSTIC METHODS OF CATEGORY A DISEASES AND TRANSPORT OF SAMPLES (referred to in Article 3), Regulation (EU) 2026/322

In forcesince 12 Feb 2026
1.

Clinical examinations must include, if possible:

(a)

animals showing clinical signs of category A diseases;

(b)

animals likely to have recently died from a suspected or confirmed category A disease;

(c)

animals with an epidemiological link to a suspected or confirmed case of a category A disease;

(d)

animals that obtained positive or non-conclusive results in previous laboratory examinations.

2.

The animals to be examined must be selected at random, in a number large enough to allow the detection of the category A disease, if present, where there are no obvious signs of disease or post-mortem lesions suggesting the presence of category A diseases.

3.

The animals to be examined and the sampling method must be chosen in accordance with the instructions of the competent authority, the relevant scientific evidence for the relevant category A disease, and with the relevant contingency plan as referred to in Article 43 of Regulation (EU) 2016/429. The animals to be examined and the sampling method must take into account the disease profile, and:

(a)

the purpose of the sampling;

(b)

the listed species kept in the establishment;

(c)

the number of animals of listed species kept in the establishment;

(d)

the category of the kept animals;

(e)

the available production, health and traceability records of the kept animals relevant for the investigation;

(f)

the type of establishment and the husbandry practices;

(g)

the level of exposure risk taking into account:

(i)

the likelihood of exposure to the category A disease agent or to the vector;

(ii)

the absence of immunisation of the animals due to vaccination or maternal immunity;

(iii)

the history of residence in the establishment;

(h)

other relevant epidemiological factors.

4.

The minimum number of animals to be examined must be in accordance with the instructions of the competent authority, and with the relevant contingency plan as referred to in Article 43 of Regulation (EU) 2016/429. The minimum number of animals to be examined must take into account the relevant category A disease profile, and in particular:

(a)

the expected prevalence of the relevant category A disease in the establishment;

(b)

the level of confidence desired of the survey results, which in any case must not be lower than 95 %;

(c)

international standards and the relevant scientific evidence for the relevant category A disease.

1.

Sampling for laboratory examinations must take into account the outcome of the clinical examinations referred to in point A.1 and, if possible, must include the animals referred to in paragraph 1 of point A.1.

2.

If there are no obvious signs of disease or post-mortem lesions suggesting category A diseases, samples must be collected at random in each epidemiological unit of the establishment and must allow the detection of the relevant category A disease, if present.

3.

The animals to be sampled, the nature of the samples to be collected and the sampling method must be in accordance with the instructions of the competent authority, the relevant scientific evidence for the relevant category A disease, the relevant details and guidance of the European Union Reference Laboratories (EURL) and of the Commission, and with the relevant contingency plan referred to in Article 43 of Regulation (EU) 2016/429. The animals to be sampled, the nature of the samples to be collected and the sampling method must take into account the relevant category A disease profile and the criteria set out in paragraph 3 of point A.1.

4.

The minimum number of animals to be sampled must be in accordance with the instructions of the competent authority, the relevant scientific evidence for the relevant category A disease, the relevant details and guidance of the EURL and of the Commission, and the relevant contingency plan referred to in Article 43 of Regulation (EU) 2016/429. The minimum number of animals to be sampled must take into account the criteria set out in paragraph 4 of point A.1 and the performance of the tests used.

5.

In the case of wild animals, samples must be collected from animals shot, found dead or purposely trapped or must be obtained on the basis of non-invasive methods such as salt licks and chewing ropes or baits. The minimum number and the nature of the samples must take into account the estimated size of the wild population and the relevant criteria set out in paragraph 3 and 4 of point A.1.

The choice of establishments where the samples are to be taken, the minimum number of establishments to be visited and the sampling method must be in accordance with the instructions of the competent authority, the relevant scientific evidence for the relevant category A disease, and with the relevant contingency plan referred to in Article 43 of Regulation (EU) 2016/429. The choice of establishments where samples are to be taken and the sampling method must take into account the relevant category A disease profile and the criteria set out in paragraph 3 of point A1.

The techniques, reference materials, their standardisation and the interpretation of the results of tests carried out using the relevant diagnostic methods for category A diseases must comply with Article 6 and with Part III of Annex VI to Delegated Regulation (EU) 2020/689.

The diagnostic methodology must aim to maximise the sensitivity of the surveillance. In certain circumstances this surveillance may include the use of laboratory examinations in order to assess previous exposure to disease.

1.

All the samples taken to confirm or rule out the presence of a category A disease must be sent, with a proper labelling and identification, to an official laboratory which has been informed of their arrival. These samples must be accompanied by the appropriate forms, in accordance with the requirements established by the competent authority and the laboratory receiving the samples. These forms must include at least:

(a)

the establishment of origin of the sampled animals;

(b)

information on the species, age and category of the sampled animals;

(c)

the clinical history of the animals, if available and relevant;

(d)

the clinical signs and post-mortem findings;

(e)

any other relevant information.

2.

All samples must be:

(a)

stored in watertight and unbreakable containers and packages and in accordance with applicable international standards;

(b)

kept at the most appropriate temperature and other conditions during transport taking into account the factors that may affect the sample quality.

3.

The exterior of the package must be labelled with the address of the recipient laboratory and the following message must be prominently displayed:

‘Animal pathological material; perishable; fragile; do not open outside the laboratory of destination.’

4.

The person responsible in the official laboratory receiving the samples must be informed in due time of the arrival of the samples.